Castle Biosciences published a prospective validation study in the Journal of the American Academy of Dermatology showing that its AdvanceAD-Tx gene expression profile test can identify patients with moderate-to-severe atopic dermatitis who are significantly more likely to achieve faster and deeper clinical responses with JAK inhibitor therapy. Approximately 30% of patients studied had a JAK Inhibitor Responder Profile and were 5.5 times more likely to achieve EASI-90 improvement by three months compared to those on Th2-targeted therapies (45.5% vs. 8.3%). The test launched in limited commercial access in late 2025.

A systematic review and meta-analysis demonstrates that TissueCypher® Barrett's Esophagus test can more accurately identify patients at risk of developing esophageal cancer compared to traditional pathology methods.

Castle Biosciences has been named a Houston Top Workplace for the fifth consecutive year, earning recognition for employee culture, including awards in Employee Appreciation, Employee Well-Being, and Professional Development.

Castle Biosciences announced its Q3 2025 financial results and launched AdvanceAD-Tx, a genetic expression test to help guide systemic treatment decisions for patients with moderate-to-severe atopic dermatitis aged 12 and older.

Castle Biosciences presented research demonstrating its TissueCypher test can provide advanced risk insights for Barrett's esophagus patients, potentially helping clinicians identify and intervene earlier for patients at higher risk of esophageal cancer progression.

Castle Biosciences will release its Q3 2025 financial results on November 3, 2025, after market close, with a conference call and webcast to discuss the results at 4:30 p.m. Eastern time.

Castle Biosciences was named to Newsweek's inaugural 2025 America's Greatest Companies list, highlighting the company's strong performance in financial strength, workforce dedication, innovation, and corporate sustainability.

A study revealed that TissueCypher can identify 15% of non-dysplastic Barrett's esophagus patients with high progression risk to esophageal cancer, potentially enabling more personalized surveillance and treatment strategies.

The FDA is tightening survival standards in cancer research, with private investments helping to fill public funding gaps. Several biotech companies are advancing innovative immunotherapies, with Oncolytics Biotech showing promising results in pancreatic cancer treatment.

Castle Biosciences announced its CEO Derek Maetzold was named a 2025 Most Admired CEO by the Houston Business Journal and received FDA Breakthrough Device designation for its DecisionDx-Melanoma test.

Castle Biosciences' CEO Derek Maetzold was honored by the Houston Business Journal as a 2025 Most Admired CEO, recognizing his leadership in developing innovative diagnostic tests for various medical conditions.

Castle Biosciences announced its DecisionDx-Melanoma test received FDA Breakthrough Device designation, highlighting the test's potential to improve melanoma patient outcomes through personalized risk stratification and prediction of lymph node positivity.